Why the study?
Do LMWHs, DOACs, or other anticoagulants reduce recurrent VTE or mortality compared to VKAs or each other in people with cancer and symptomatic VTE?
Do LMWHs, DOACs, or other anticoagulants reduce recurrent VTE or mortality compared to VKAs or each other in people with cancer and symptomatic VTE?
In cancer patients with VTE, LMWHs reduce VTE recurrence compared to VKAs, while DOACs may further reduce VTE recurrence compared to LMWHs but at the cost of increased major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports LMWH over VKA to reduce VTE recurrence in cancer; confirms benefit while leaving DOAC choice open due to bleeding risk.
Kahale et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: